New Hampshire Board of Medicine Recognizes Venebio Opioid Advisor™ as Approved Prescription Opioid Risk Assessment Tool
RICHMOND, Va. – January 31, 2018 – The New Hampshire Board of Medicine has approved Venebio Opioid Advisor™ (VOA™) as one of the state’s official risk assessment tools for opioid prescribing. New Hampshire state law requires that any opioid risk assessment tool be approved by the New Hampshire Board of Medicine. The […]
Comprehensive analysis of U.S. prescription opioid users and overdose cases further supports personalized approach to prescription of opioids. RICHMOND, Va. – January 15, 2017 – Individuals suffering from a substance use disorder (SUD) or depression are among those at highest risk for a serious prescription opioid overdose, according to a study […]
Study Validating Venebio Opioid Advisor’s Ability to Identify Patients at Risk of Prescription Opioid Overdose Published in Pain Medicine
Venebio Opioid Advisor is the only validated tool to predict the likelihood of a life-threatening opioid overdose with 90-percent accuracy. RICHMOND, Va. – January 15, 2017 – A study validating the strong performance of Venebio Group’s risk-screening tool for prescription opioid overdose — Venebio Opioid Advisor™ (VOA™) — has been published in the January […]
GAO Report: CMS Needs to Broaden Opioid Efforts to Identify and Address Those at Risk for Serious Harm
The Centers for Medicare and Medicaid Services (CMS) have focused for years on identifying opioid-treated beneficiaries at risk for serious harm such as overdose or addiction. Their approach has concentrated on patients prescribed high daily doses of opioids who also have indicators of opioid misuse or abuse, such as ‘doctor […]
A recent study conducted at Brigham and Women’s Hospital showed that an opioid overdose patient who receives Naloxone and recovers from the overdose, and is subsequently discharged has a one-in-ten chance of dying within a year. The authors acknowledge that Naloxone is an important tool in fighting the opioid crisis, but does not provide […]
Although the adoption of PDMPs is an effort that holds promise, their ability to stem opioid overprescribing is inherently limited by the specific form of misuse that the programs aim to address. Read more in this insightful Brookings Op-Ed here.
The devastation of the nation’s opioid epidemic does not need further explanation. Seemingly every day, news stories underscore the fact that opioid overdose knows no gender, race or class boundaries. Too few of these stories, however, speak of available solutions to combat this epidemic. Read the full article by Mark […]
Venebio’s Chief Medical Officer, Barb Zedler, M.D., penned an opinion piece in response to an interim report from President Trump’s Commission on Combating Drug Addiction and the Opioid Crisis, which was published in the Philadelphia Inquirer. Read the piece here.
Venebio Opioid Advisor and Venebio’s efforts to address the opioid overdose epidemic were featured in Virginia Business magazine. Read the article here.
Venebio Group will present at the upcoming Health 2.0 Annual Fall Conference in Santa Clara, CA on October 2, 2017. During the presentation, Mr. Mark Tripodi, Venebio’s Chief Development Officer, will highlight the Venebio Opioid Advisor clinical decision support tool and its benefits toward safer opioid prescribing.